Northwestern Medicine®

Muscle-Invasive Bladder Cancer

Northwestern Medicine Palos Hospital St. George Foundation Continuing Education Series

Presented by Joshua Meeks, MD, PhD, and Timothy Kuzel, MD

Dr. Meeks is an associate professor of Urology, Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, and section chief of Robotic Surgery at Jesse Brown VA Medical Center. He is a urologic surgeon with expertise in bladder cancer. Dr. Meeks' research interests focus on epigenetic and genetic mutations associated with cancer biology, specifically the role chromatin remodeling genes play in bladder cancer.



Joshua Meeks, MD, PhD

With a storied career in oncology and long-standing interest in immunotherapy approaches, Dr. Kuzel is a clinical professor of Medicine at Feinberg School of Medicine, oncology service line director of the south region of Northwestern Medicine, and an associate director at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He has authored or co-authored over 350 journal articles, editorials, and book chapters and has edited several textbooks.

Timothy Kuzel, MD

Learning Objectives

- Describe the different options for peri operative treatment of muscle invasive bladder cancer.
- Appreciate the spectrum of toxicities associated with endortumab, vedoitin and pembrolizumab.

Accreditation Statement

The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Surgery-Accredited CME

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit. CME credits will be submitted to the board by the end of the calendar year.

Session

Thursday, Nov 19
7:30 – 8:30 am

How to attend

In person:
Attend the live event at the St. George Cancer Institute Auditorium.

Light breakfast will be served.

Microsoft Teams:
Join the meeting now

Or call in (audio only): 872.240.1267
Phone Conference ID: 649 574 767#

Course Director

James O. Draguesku, MD

Disclosure Statements

Dr. Meeks has ownership interest in Meshsuture. He receives honorarium from Astellas; AstraZeneca; AUA; Ferring; Imvax; Johnson and Johnson; Merck and Company, Inc.; Olympus; Pfizer, Inc.; Prokarium; and Urogen. He received honorarium from Axiom; Bristol-Myers Squibb; CG Oncology; Immunity Bio; Photocure; Platform Q; and Protara. He received grant research support from Merck and Company, Inc. and Epizyme. These relationships have ended.

Dr. Kuzel is an advisor for AstraZeneca; Cardinal Health; CVS; Engene; Fidia Therapeutics; Merck and Company, Inc.; Pfizer, Inc.; and UpToDate. He served as an advisor for Daiichi Sankyo; this relationship has ended.

All the relevant financial relationships have been mitigated. The course director, Dr. Draguesku and Karen Bertucci, MEd, CME specialist, have no relevant financial relationships with ineligible companies to disclose. The Northwestern University Feinberg School of Medicine CME leadership, review committee and staff have no relevant financial relationships with ineligible companies to disclose.

For more information, please contact **karen.bertucci@nm.org**.

This educational program is supported by the St. George Foundation.